NRIX Nurix Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NRIX

Price (delayed)

$25.7

Market cap

$2.81B

P/E Ratio

10.28

Dividend/share

N/A

EPS

$2.5

Enterprise value

$2.15B

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 93
Relative Valuation: Rel. Valuation: 90
Relative Profitability: Rel. Profitability: 99

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving ...

Highlights
The net income has surged by 186% since the previous quarter
NRIX's EPS has surged by 184% year-on-year and by 172% since the previous quarter
NRIX's debt is up by 16% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nurixtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of NRIX

NRIX stock price

How has the Nurix Therapeutics stock price performed over time
Intraday
-4.1%
1 week
0.59%
1 month
11.79%
1 year
98.61%
YTD
35.48%
QTD
8.39%

Financial performance

How have Nurix Therapeutics's revenue and profit performed over time
Revenue
$701.94M
Gross profit
$701.94M
Operating income
$289.66M
Net income
$294.88M
Gross margin
100%
Net margin
42%
The net income has surged by 186% since the previous quarter
The operating income has surged by 180% since the previous quarter
NRIX's net margin has surged by 114% year-on-year and by 105% since the previous quarter
Nurix Therapeutics's operating margin has surged by 113% YoY and by 104% QoQ

Price vs fundamentals

How does NRIX's price correlate with its fundamentals

Growth

What is Nurix Therapeutics's growth rate over time

Valuation

What is Nurix Therapeutics stock price valuation
P/E
10.28
P/B
2.75
P/S
4.08
EV/EBIT
6.98
EV/EBITDA
6.64
EV/Sales
3.07
NRIX's EPS has surged by 184% year-on-year and by 172% since the previous quarter
NRIX's equity has surged by 160% year-on-year and by 140% since the previous quarter
The stock's price to book (P/B) is 17% less than its last 4 quarters average of 3.3 but 6% more than its 5-year quarterly average of 2.6
The stock's price to sales (P/S) is 84% less than its last 4 quarters average of 25.1 and 78% less than its 5-year quarterly average of 18.5

Efficiency

How efficient is Nurix Therapeutics business performance
NRIX's return on assets has surged by 195% year-on-year and by 167% since the previous quarter
The ROE has soared by 192% YoY and by 165% from the previous quarter
NRIX's return on invested capital has surged by 191% since the previous quarter
NRIX's return on sales has surged by 115% year-on-year and by 105% since the previous quarter

Dividends

What is NRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NRIX.

Financial health

How did Nurix Therapeutics financials performed over time
The total assets has surged by 129% year-on-year and by 123% since the previous quarter
Nurix Therapeutics's total liabilities has surged by 71% QoQ and by 51% YoY
NRIX's debt is 93% smaller than its equity
NRIX's equity has surged by 160% year-on-year and by 140% since the previous quarter
The debt to equity has dropped by 53% year-on-year and by 50% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.